



2021 Taipei International Breast Cancer Symposium

台北國際乳癌研討會

What tumor biology makes the difference in patients treated with CDK4/6 inhibitors?

Eva Ciruelos

Medical Oncologist and Coordinator of the Multidisciplinary Breast Cancer Unit,
the University Hospital 12 de Octubre

Coordinator of Breast Cancer Unit, HM private hospitals

Associate Professor, Department of Medicine,

the Complutense University of Madrid Faculty of Medicine,

Madrid, Spain

CDK4/6 inhibitors have demonstrated similar improvements in PFS in HR+, HER2- advanced breast cancer; however, the extent of OS benefit differs. These differences in OS benefit may be a result of differential development of endocrine treatment resistance over time, which is known to occur in a substantial proportion of advanced breast cancer patients. The luminal and non-luminal intrinsic subtypes have shown predictive value in HR+, HER2- ABC with respect to prognosis and response to endocrine treatment. In this session, we will summarize current evidence on different efficacy of CDK4/6 inhibitors in different tumor subtypes in HR+, HER2- advanced breast cancer and explore the possible mechanism behind.